If you have been reading about Investigational drug and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-12. Numbers and descriptions here follow the published literature rather than marketing material.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a metabolic modulator. |
| Approved medical use | None in major jurisdictions | Not a registered drug. |
| Common test matrix | Urine | Most anti-doping samples use urine. |
| Typical detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Reference standard storage | -20 °C, desiccated | Typical for analytical standards. |
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
The Moskovskaya Okruzhnaya Zheleznaya Doroga (orbital railway line) has formed a ring around Moscow's current downtown since 1903. However, this line was a non-electrified, locomotive-only railway before reconstruction into the MCC during the 2010s. The Moscow Central Circle is a 54-kilometer (34 mi) orbital urban rail transit line that encircles historic Moscow. This line was built alongside the Little Ring of the Moscow Railway, incorporating some of its tracks. The MCC was opened for passenger use on 10 September 2016. The MCC line is operated by the Moscow government-owned company MKZD through the Moscow Metro, with the federal government-owned Russian Railways as the operations subcontractor.
==== English-language ==== A 2013 systematic review of the English-language case reports found that serious adverse events associated with acupuncture are rare, but that acupuncture is not without risk. Between 2000 and 2011 the English-language literature from 25 countries and regions reported 294 adverse events. The majority of the reported adverse events were relatively minor, and the incidences were low. For example, a prospective survey of 34,000 acupuncture treatments found no serious adverse events and 43 minor ones, a rate of 1.3 per 1000 interventions. Another survey found there were 7.1% minor adverse events, of which 5 were serious, amid 97,733 acupuncture patients. The most common adverse effect observed was infection (e.g. mycobacterium), and the majority of infections were bacterial in nature, caused by skin contact at the needling site. Infection has also resulted from skin contact with unsterilized equipment or with dirty towels in an unhygienic clinical setting. Other adverse complications included five reported cases of spinal cord injuries (e.g. migrating broken needles or needling too deeply), four brain injuries, four peripheral nerve injuries, five heart injuries, seven other organ and tissue injuries, bilateral hand edema, epithelioid granuloma, pseudolymphoma, argyria, pustules, pancytopenia, and scarring due to hot-needle technique.
Giddings also envisioned the capabilities of Supercritical fluid chromatography, by developing the theory and ground work of dense gas chromatographic system. Eventually Prof Giddings invented the one-phase separation technique called "field-flow fractionation" (FFF). He developed the concept of a chromatographic-like system in which retention is established and controlled by an external field rather than by the stationary phase. The FFF system extends the range of chromatography upward to include macromolecules and particles of almost every type and size, from 0.001 to 10 μm and beyond. He was nominated for a Nobel Prize in 1984 and 1994. Giddings received numerous honors for his work including American Chemical Society Awards in Chromatography and Electrophoresis, in Analytical Chemistry, and in Separation Science and Technology. He also received the Tswett Medal in Chromatography, and the Nichols Medical from the New York Section of the ACS. On May 27, 1987, Giddings received an honorary doctorate from the faculty of pharmacy at Uppsala University, Sweden He died of cancer in 1996.
Sources: en.wikipedia.org
The precise reason why there are only four nucleotides is debated, but there are several unused possibilities. Furthermore, adenine is not the most stable choice for base pairing: in Cyanophage S-2L, diaminopurine (DAP) is used instead of adenine. Diaminopurine basepairs perfectly with thymine as it is identical to adenine but has an amine group at position 2 forming 3 intramolecular hydrogen bonds, eliminating the major difference between the two types of basepairs (weak A-T vs strong C-G). This improved stability affects protein-binding interactions that rely on those differences. Other combination include:
Pregabalin was approved for medical use in the United States in 2004. In the US, pregabalin is a Schedule V controlled substance under the Controlled Substances Act of 1970, which means it has low abuse potential compared to substances in Schedules I–IV, though there is still a potential for misuse. It is available as a generic medication. In 2023, it was the 78th most commonly prescribed medication in the United States, with more than 8 million prescriptions.
There is evidence to show that schizophrenia, as a neural phenomenon, is associated with both hyper- and hypoglutamatergic function, mediated by NMDA receptors. Dysfunction of NMDA receptors, and the corresponding hypoglutamatergic signaling, produces overstimulation ionotropic receptors and leads to excitotoxicity.
Sources: en.wikipedia.org
Archival Resources Details Thorburn Brailsford Robertson: Repository: Commonwealth Scientific and Industrial Research Organisation (CSIRO) Corporate Records and Archives Strategies, The Encyclopedia of Australian Science and Innovation. Robertson, Thorburn Brailsford (1884–1930), The Encyclopedia of Australian Science and Innovation. Thorburn Brailsford Robertson, Adelaide Connect, University of Adelaide. Lehmann Jayne, "World Diabetes Day – Time to celebrate Adelaide’s link to 1922 insulin discovery", EdHealth Australia, 14 November 2016. Thorburn Brailsford Robertson, South Australian Medical Heritage Society. TROVE: "From the library of Thorburn Brailsford Robertson".
Shortly after the discovery of the neutron in 1932, Enrico Fermi realized that certain rare beta-decay reactions immediately yield neutrons as an additional decay particle, so called beta-delayed neutron emission. Neutron emission usually happens from nuclei that are in an excited state, such as the excited 17O* produced from the beta decay of 17N. The neutron emission process itself is controlled by the nuclear force and therefore is extremely fast, sometimes referred to as "nearly instantaneous". Isolated proton emission was eventually observed in some elements. It was also found that some heavy elements may undergo spontaneous fission into products that vary in composition. In a phenomenon called cluster decay, specific combinations of neutrons and protons other than alpha particles (helium nuclei) were found to be spontaneously emitted from atoms.
=== Eye morphology === The lens of the eye changes in curvature. Because of decreased androgen levels, the meibomian glands (the sebaceous glands on the upper and lower eyelids that open up at the edges) produce less oil. Because oil prevents the tear film from evaporating, this change may cause dry eyes.
==== Internationals that emerged from the Fourth International (USFI) ==== Fourth International Posadist (1962) Committee for a Workers' International, CWI (1974) refounded with the same name after a 2019 split. International Socialist Tendency, IST (1979) founded by expelled members of the original Fourth International in the 1950s International Workers League – Fourth International, IWL-FI (1982) founded by former members of the USFI. Current for the Permanent Revolution - Fourth International, CPR-FI (1989) Previously named Trotskyist Fraction - Fourth International. Founded by expelled members of the IWL-FI Pathfinder Tendency, (1990) based on USA SWP Revolutionary Communist International, RCI (1992). Split from CWI. Previously named International Marxist Tendency, IMT (2004–2024), and the Committee for a Marxist International, CMI (1992–2004) International Workers' Unity – Fourth International, IWU-FI (1997) split from IWL-FI. International Leninist Trotskyist Fraction, ILTF (1998) split from the TF-FI Tendency for the Reconstruction of the Fourth International, (2006) formed by expelled members of the TF-FI. International Revolutionary Left, (2010) split from IMT in 2010 and the CWI in 2019 Revolutionary Communist International Tendency, RCIT (2011) founded by former members of the IST and L5I. International Socialist League, ISL-LIS (2019) International Socialist Alternative, ISA (2020) claims to be successor to the CWI after the 2019 split. ISA-R ( external faction) Internationalist Standpoint, IS (2022) split from International Socialist Alternative.
Sources: en.wikipedia.org
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.
Anti-doping laboratories use LC-MS/MS to detect GW501516 and its metabolites, usually in urine. The method can identify the parent compound at low concentrations. Detection windows vary with dose and individual factors.
No, cardarine has no approved medical uses in major jurisdictions. Early research explored metabolic conditions, but those programs were discontinued. It is not a registered treatment for any disease.
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.